Progress on predictive methods for loss of response to infliximab treatment in pediatric Crohn's disease
10.3760/cma.j.issn.1673-4408.2024.04.005
- VernacularTitle:克罗恩病患儿英夫利昔单抗治疗失应答预测方法研究进展
- Author:
Yang YUE
1
;
Hongmei GUO
Author Information
1. 南京医科大学附属儿童医院消化内科 210008岳阳现在南京医科大学附属常州第二人民医院儿科 213000
- Keywords:
Infliximab;
Crohn's disease;
Loss of response;
Prediction
- From:
International Journal of Pediatrics
2024;51(4):236-239
- CountryChina
- Language:Chinese
-
Abstract:
Infliximab is one of the most extensively used biological agents in the treatment of Crohn's disease，but in the actual application process，some patients may have loss of response，which may lead to the refactory disease and the rise of treatment cost.Identifying loss of response at an early phase has become a crucial component of treatment，but the academic community has not a unified prediction standard yet.This article reviews the recent indicators for predicting loss of response to infliximab treatment，such as infliximab concentration and anti-antibody monitoring，serological indicators，ultrasound，magnetic resonance imaging and endoscopy，clinical indicators of Crohn's disease，HLA-DQA1*05 gene，newly developed models and indicators and their criteria.
